Abstract
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Marissa N Lassere, Kent R Johnson, Maarten Boers, Peter Tugwell, Peter Brooks, Lee Simon, Vibeke Strand, Philip G Conaghan, Mikkel Ostergaard, Walter P Maksymowych, Robert Landewe, Barry Bresnihan, Paul-Peter Tak, Richard Wakefield, Philip Mease, Clifton O Bingham 3rd, Michael Hughes, Doug Altman, Marc Buyse, Sally Galbraith and George Wells
The Journal of Rheumatology March 2007, 34 (3) 607-615;
Marissa N Lassere
Kent R Johnson
Maarten Boers
Peter Tugwell
Peter Brooks
Lee Simon
Vibeke Strand
Philip G Conaghan
Mikkel Ostergaard
Walter P Maksymowych
Robert Landewe
Barry Bresnihan
Paul-Peter Tak
Richard Wakefield
Philip Mease
Clifton O Bingham 3rd
Michael Hughes
Doug Altman
Marc Buyse
Sally Galbraith
In this issue
The Journal of Rheumatology
Vol. 34, Issue 3
1 Mar 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Marissa N Lassere, Kent R Johnson, Maarten Boers, Peter Tugwell, Peter Brooks, Lee Simon, Vibeke Strand, Philip G Conaghan, Mikkel Ostergaard, Walter P Maksymowych, Robert Landewe, Barry Bresnihan, Paul-Peter Tak, Richard Wakefield, Philip Mease, Clifton O Bingham, Michael Hughes, Doug Altman, Marc Buyse, Sally Galbraith, George Wells
The Journal of Rheumatology Mar 2007, 34 (3) 607-615;
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Marissa N Lassere, Kent R Johnson, Maarten Boers, Peter Tugwell, Peter Brooks, Lee Simon, Vibeke Strand, Philip G Conaghan, Mikkel Ostergaard, Walter P Maksymowych, Robert Landewe, Barry Bresnihan, Paul-Peter Tak, Richard Wakefield, Philip Mease, Clifton O Bingham, Michael Hughes, Doug Altman, Marc Buyse, Sally Galbraith, George Wells
The Journal of Rheumatology Mar 2007, 34 (3) 607-615;